RNAZ TransCode Therapeutics Inc

$RNAZ Every green candle is an opportunity to short. They're highly dilutive as their overhead supply is massive and their cash is very low. They're going to need to raise money and they're going to do so by selling shares. I'm just shorting alongside the ride making 20k a move. Love this one!!! 💰💰💰💰💰💰💰💰💰💰💰💰💰💰

$RNAZ delivered encouraging Phase 1a data showing 71% stable disease and extended treatment duration for TTX-MC138.

$RNAZ May be finding support here, considering an entry soon….only discouraged by the fast sell offs…we’ll see 👀💸💰

$RNAZ I just saw an ad on CNBC so came to take a look. My first red flag was the ad proclaiming Harvard Med professionals in this company. Then I took a look at it. Good grief! How much dilution is enough for their investors?

$RNAZ The market cap is about $34 million which includes all options and warrants as shares. This cap is typical of a company having only a promising P1 drug. Management is filled will Harvard Medical and Mass General doctors. That's good enough for me. The company has proven concept. There are no material safety hazards. Efficacy has been initially shown able to hold metastasized cancer in check. Metastasis is the cause of about 90% of actual deaths by cancer. In the not so distant future, the company will reveal Phase 2a initial top line data. Yes, they will need to raise money. The company holds a P3 ready melanoma vaccine. The company has proven a platform of delivery by nanotech of many possible API's. I don't know about you, but I think this is a major science breakthrough in cancer. I believe that this company will be worth $ billions, and billions. This is a core long position for me. The market cap should now be at about $300 million, minimum. JMO

$RNAZ More patent announcements pending in Croatia, Bosnia and Serbia. Super tough… had to apply in three different langauges..

$RNAZ First results might come toward the end of this year. Since circulating tumor DNA (ctDNA) levels can be measured relatively easily, and measurements are planned at baseline and every month after dosing with TTX-MC138, interim results should be coming relatively quickly and frequently. Any decrease in ctDNA could suggest slowing and/or halting of metastatic colorectal cancer progression. In this study, this is particularly interesting because such metastases would otherwise typically become visible by CT/MRI within one year in the same patients.

$RNAZ is trading sharply higher on partnership following a Business Wire release. Natera and TransCode Therapeutics collaborate on Phase 2a trial using Signatera MRD testing to identify colorectal cancer patients for TTX-MC138 treatment evaluation. RTPR pushed this release out to users at 7:30:00 AM ET

$RNAZ Another RS looks imminent… looks like we won’t be getting any real news, any time soon.. Shit…

$RNAZ I shared the following chart with Claude and asked where was this trending, in brief this was Claude's summary: "...Overall, it's a possible bottoming attempt but unconfirmed, and it needs follow-through above about $2.30 on rising volume..."